Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah I have been buying a lot in the past two weeks myself. Bought too high in the 60s to start but I was able to pick up a lot in the 50s so Im happy with that.
I am probably done buying unless it drops below .55, or we get some good news that I am not expecting.
THe ducks are lining up for a nice increase in share price soon. Word is starting to spread.
$TPIV TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
PR NEWSWIRE 9:15 AM ET 4/21/2016
Symbol Last Price Change
TPIV 0.61up +0.03 (+5.17%)
AZN 30up -0.17 (-0.56%)
QUOTES AS OF 09:51:59 AM ET 04/21/2016
JACKSONVILLE, Florida , April 21, 2016 /PRNewswire/ --
Study to commence Q 2 2016 at Sloan Kettering Institute
Cancer vaccine and checkpoint inhibitor combinat ion to be evaluated in platinum- resistant ovarian cancer patients
TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRa), in combination with Astra Zeneca durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study will commence in the second quarter of 2016 at Memorial Sloan Kettering Cancer Center in New York and will be led by Jason Konner, M.D. as Principal Investigator.
The two Companies will share clinical costs, while TapImmune(TPIV) will supply TPIV 200 and MedImmune will supply Durvalumab (MED14736) for the trials. TapImmune recently obtained Orphan Drug Designation for TPIV 200 in ovarian cancer from the U.S. Food and Drug Administration.
This single arm Phase 2 trial will include 40 women with high-grade ovarian, tubal, or primary peritoneal carcinomas, who have progressed within 6 months of their most recent platinum chemotherapy. The primary objective of the study is to determine the effectiveness of the combination by measuring Overall Response Rate [ORR = Complete Response (CR) + Partial Response (PR)] by RECIST and Progression Free Survival (PFS) rate at 6 months. Secondary endpoints will be safety and immune and correlation of FRa-specific immune responses with clinical efficacy.
"This collaboration is a significant event for TapImmune(TPIV)," stated Dr. Glynn Wilson, Chairman and CEO of TapImmune(TPIV). "We are delighted to bring a leading T-cell vaccine platform into this combination study and to work with AstraZeneca(AZN)/Medimmune and Sloan Kettering in a patient population that is in dire need of an effective treatment."
"This study is part of a larger Phase 2 strategy for TPIV 200 that is designed to greatly increase our understanding of the vaccine while providing clinical evidence of efficacy," Dr. Wilson added.
TPIV 200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha, which is overexpressed in multiple cancers including over 90% of ovarian cancer cells. In Phase I clinical studies conducted at the Mayo Clinic in patients with breast and ovarian cancer, this vaccine was shown to be safe and well tolerated and to give robust cellular immune responses in 20 out of 21 evaluable patients.
About Durvalumab (MEDI4736)
Durvalumab is an investigational human monoclonal antibody directed against PD-L1 developed at MedImmune LLC. Signals from PD-L1 help tumors avoid detection by the immune system. Durvalumab blocks these signals, countering the tumor's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Durvalumab is being investigated in an extensive clinical trial program, as monotherapy or in combination with tremelimumab, in NSCLC, head and neck, gastric, pancreatic, bladder and blood cancers.
About Medimmune/AstraZeneca(AZN)
MedImmune, LLC, is the global biologics research and development arm of AstraZeneca(AZN) and is located in Gaithersburg, Md., one of AstraZeneca's(AZN) three global R&D centers. For more information, please visit http://www.medimmune.com.
AstraZeneca (AZN) is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. For more information please visit http://www.astrazeneca.com.
About TapImmune Inc.(TPIV)
TapImmune Inc. (TPIV) is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. For more information please visit http://www.tapimmune.com.
$TPIV - partnership news with AZN
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
PR NEWSWIRE 9:15 AM ET 4/21/2016
Symbol Last Price Change
TPIV 0.61up +0.03 (+5.17%)
AZN 30up -0.17 (-0.56%)
QUOTES AS OF 09:51:59 AM ET 04/21/2016
JACKSONVILLE, Florida , April 21, 2016 /PRNewswire/ --
Study to commence Q 2 2016 at Sloan Kettering Institute
Cancer vaccine and checkpoint inhibitor combinat ion to be evaluated in platinum- resistant ovarian cancer patients
TapImmune,Inc. (TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, announced today plans to initiate a Phase 2 trial of its cancer vaccine, TPIV 200, a multi-epitope anti-folate receptor vaccine (FRa), in combination with Astra Zeneca durvalumab (MEDI4736), an anti-PD-L1 antibody, in patients with platinum-resistant ovarian cancer. The study will commence in the second quarter of 2016 at Memorial Sloan Kettering Cancer Center in New York and will be led by Jason Konner, M.D. as Principal Investigator.
The two Companies will share clinical costs, while TapImmune(TPIV) will supply TPIV 200 and MedImmune will supply Durvalumab (MED14736) for the trials. TapImmune recently obtained Orphan Drug Designation for TPIV 200 in ovarian cancer from the U.S. Food and Drug Administration.
This single arm Phase 2 trial will include 40 women with high-grade ovarian, tubal, or primary peritoneal carcinomas, who have progressed within 6 months of their most recent platinum chemotherapy. The primary objective of the study is to determine the effectiveness of the combination by measuring Overall Response Rate [ORR = Complete Response (CR) + Partial Response (PR)] by RECIST and Progression Free Survival (PFS) rate at 6 months. Secondary endpoints will be safety and immune and correlation of FRa-specific immune responses with clinical efficacy.
"This collaboration is a significant event for TapImmune(TPIV)," stated Dr. Glynn Wilson, Chairman and CEO of TapImmune(TPIV). "We are delighted to bring a leading T-cell vaccine platform into this combination study and to work with AstraZeneca(AZN)/Medimmune and Sloan Kettering in a patient population that is in dire need of an effective treatment."
"This study is part of a larger Phase 2 strategy for TPIV 200 that is designed to greatly increase our understanding of the vaccine while providing clinical evidence of efficacy," Dr. Wilson added.
TPIV 200 is a multi-epitope peptide vaccine that targets Folate Receptor Alpha, which is overexpressed in multiple cancers including over 90% of ovarian cancer cells. In Phase I clinical studies conducted at the Mayo Clinic in patients with breast and ovarian cancer, this vaccine was shown to be safe and well tolerated and to give robust cellular immune responses in 20 out of 21 evaluable patients.
About Durvalumab (MEDI4736)
Durvalumab is an investigational human monoclonal antibody directed against PD-L1 developed at MedImmune LLC. Signals from PD-L1 help tumors avoid detection by the immune system. Durvalumab blocks these signals, countering the tumor's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to empower the patient's immune system and attack the cancer. Durvalumab is being investigated in an extensive clinical trial program, as monotherapy or in combination with tremelimumab, in NSCLC, head and neck, gastric, pancreatic, bladder and blood cancers.
About Medimmune/AstraZeneca(AZN)
MedImmune, LLC, is the global biologics research and development arm of AstraZeneca(AZN) and is located in Gaithersburg, Md., one of AstraZeneca's(AZN) three global R&D centers. For more information, please visit http://www.medimmune.com.
AstraZeneca (AZN) is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. For more information please visit http://www.astrazeneca.com.
About TapImmune Inc.(TPIV)
TapImmune Inc. (TPIV) is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. For more information please visit http://www.tapimmune.com.
$TPIV - BE SURE TO CHECK OUT partnership news with AZN
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
http://finance.yahoo.com/news/tapimmune-announces-phase-2-ovarian-131500507.html
Plus partnership with Mayo Clinic.
All beginning soon.
Watch closely.
$TPIV - partnership news with AZN - READY TO BREAK OUT SOON
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
http://finance.yahoo.com/news/tapimmune-announces-phase-2-ovarian-131500507.html
GOING HIGHER
$TPIV - partnership news with AZN
TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
http://finance.yahoo.com/news/tapimmune-announces-phase-2-ovarian-131500507.html
GOING HIGHER
TPIV ABOUT TO GET PUMPED UP. GET YER SHARES WHILE THEY ARE CHEAP!
$TPIV - been buying past two weeks. Could be a good runner shortly
Agreed. Cant wait for the trials to begin.
Man feel bad for those who got punked out of their shares today. MY only regret was not acquiring more in the mid 50s. Will be ready if we get that opportunity again.
We should start to get some positive coverage here too. News outlets will pick up on this gem.
This news is fantastic
FWIW partnering with AZN was better than I expected. That gives major credence to TPIV
Loved how it moved to .80+ on the anticipation of partnership news, and now that we get it, it's stuck in the low .60s. What t thing the stock market is.
Oh well, we should have a string of good days ahead. Esp as the trials actually kick off.
Anyone think AZN will buy TPIV? They recently bought ZS Pharma for 2.7 BILLION before its product is FDA accepted. And prior to long term safety results.
Same!!
My 3k shares purchased at .586 are looking pretty SWEEEEEEEEEEET right now. Lets go!
Bought more in .50s. Feeling comfortable sitting here for a few weeks.
Interview with Glynn, posted mid March.
http://stocknewsnow.com/commentary/ANEWSID16032016100001/SNNLive-Video-Interview-Update-with-TapImmune-Inc-
The video was actually recorded 2/11.
Anything is possible but it seems unlikely.
The CEO has been interviewed on TV by news outlets, and the company has made presentations, both stating a partnership is imminent, all within the past 20 or so days.
What is more likely is that things take a few days longer to get finalized by a small company than originally anticipated. In the fullness of time, a few days or even a week or two delay is no big deal. Just presents a short term buying opp for those who missed last weeks runup - like myself.
This will be a big disappointment if we don't get a dip to the low. 60 today.
Want more shares...
I have my buys in several cents lower for the inevitable dip. Very excited to be building a position in the .60 given what's coming.
Buying all dips strong today again....if we get any....
LOADED THE BOAT ON TODAY'S DIP.
What a great opportunity with news/multiple catalyst's right around the corner!!
What a joke of a market cap for QURE. ONCE & BLUE in the billions. BILLIONS I SAY!!!!!!!
Enormous upside.
$QURE +10% undervalued bio stock. Breaking out with near term catalyst.
LOW FLOATER!!!!!!
Love QURE
$QURE +10% undervalued bio stock
Bought on the dip yesterday, then JBEM releases QURE as his pick. What luck!!!!
Easy 2 bagger. PT $40 in a few months
Realistic expectations for p2a data? I'm still thinking we see it sometime tomorrow.
Energy Play: WLTGQ ready to go parabolic, 50%+ Friday and looking for continuation of trend.
WLTGQ ready to go parabolic, 50%+ Friday and looking for continuation of trend.
WLTGQ: check out ANRZQ it's up 30% today. WLT has some catching up to do. Both should rock short term with energy stocks going parabolic
Expecting to see a continuation of Friday's action. A few oil companies (BTU. MPO) are up sharply in pre-market; this bodes will for ANRZQ
Agreed. ANd this one will fill sooner or later. If/when it does that's 400% on my money fro, current levels. Nibbled a good bit today and Im anxious to see whatnext week brings us!
Lots of interest in coal stocks lately too, only a matter of time before this runs.
Looking for gap fill at .20 - represents a 400% upside swing.
Have a great weekend too!
ANRZQ Capitulation in coal stocks - just see ACI for example. Heading much higher.
Capitulation in coal stocks. Heading to .50 eventually. Buy and hold!